{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:52:54Z","timestamp":1776750774552,"version":"3.51.2"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment for triple-negative breast cancer (TNBC) is challenging due to its aggressive nature and its high metastatic potential. This breast cancer subtype is characterized by the presence of highly proliferative cells with great ability to promote lymphangiogenesis and facilitate metastasis to regional lymph nodes (LNs). Indeed, the physical presence of breast cancer cells in regional LNs is an important prognostic factor. Moreover, tumor-associated lymphangiogenesis within the TNBC microenvironment plays a crucial role not only providing new routes for the metastatic spread of cancer cells but also delineating tumor immunity. As such, modulating tumor-associated vasculature by combination immunotherapy could be a promising strategy to treat TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we have conducted a comprehensive review of previously published works using PubMed and Web of Science databases for studies addressing immunotherapy and lymphangiogenesis in TNBC. Inclusion criteria were applied to identify relevant preclinical and clinical studies focusing on the intersection of immune-based therapies and the tumor lymphatic network. A total of 59 eligible articles were identified and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our findings indicate that, while immunotherapy is an effective clinical strategy to treat TNBC, current strategies rarely incorporate agents targeting tumor-associated lymphangiogenesis. The reviewed studies suggest that lymphatic vessels within the TNBC microenvironment are not only structural pathways for metastasis but also dynamic regulators of immune cell trafficking and tumor immune evasion. Despite this, the therapeutic potential of combining immunotherapy with lymphangiogenesis-targeting agents remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite clear evidence supporting the role of lymphangiogenesis in TNBC progression and immune regulation, its integration into immunotherapy regimens remains largely unexplored. Therefore, the development of novel combination strategies based on immunotherapy and agents targeting lymphatic vessels and their crosstalk with immune and cancer cells within the TNBC microenvironment would greatly improve the response of TNBC patients to immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1641259","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:33:56Z","timestamp":1776749636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Modulation of tumor-associated lymphangiogenesis by combination immunotherapy approaches in triple-negative breast cancer: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Mar\u00eda","family":"Guerrero-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Biomedical Research Institute of M\u00e1laga and Nanotechnology Platform (IBIMA-Plataforma BIONAND)","place":["M\u00e1laga, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Martens","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Life Sciences, Hasselt University","place":["Diepenbeek, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Garc\u00eda-Caballero","sequence":"additional","affiliation":[{"name":"Biomedical Research Institute of M\u00e1laga and Nanotechnology Platform (IBIMA-Plataforma BIONAND)","place":["M\u00e1laga, Spain"]},{"name":"Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of M\u00e1laga","place":["M\u00e1laga, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.36255\/exon-publications-breast-cancer-subtypes","article-title":"Subtypes of breast cancer","volume-title":"Breast cancer","author":"Orrantia-Borunda","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.21037\/atm.2020.04.37","article-title":"Understanding breast cancer disparities\u2014a multi-scale challenge","volume":"8","author":"Hill","year":"2020","journal-title":"Ann Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pbiomolbio.2019.11.007","article-title":"Recent treatment progress of triple negative breast cancer","volume":"151","author":"Chang-Qing","year":"2020","journal-title":"Prog Biophys Mol Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.21635","article-title":"Risk factors and preventions of breast cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int J Biol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: Future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2019","journal-title":"Medicina"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26123494","article-title":"Natural compounds as metabolic modulators of the tumor microenvironment","volume":"26","author":"Dias","year":"2021","journal-title":"Molecules"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113290","article-title":"The roles of non-coding RNAs in tumor-associated lymphangiogenesis","volume":"12","author":"Yusof","year":"2020","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010004","article-title":"Lymphatic endothelial markers and tumor lymphangiogenesis assessment in human breast cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Diagnostics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.862326","article-title":"Anti-angiogenetic and anti-lymphangiogenic effects of a novel 2-aminobenzimidazole derivative, MFB","volume":"12","author":"Hsu","year":"2022","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13402-016-0281-9","article-title":"The role of lymphangiogenesis and angiogenesis in tumor metastasis","volume":"39","author":"Paduch","year":"2016","journal-title":"Cell Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathophys.2009.11.003","article-title":"Lymphangiogenesis and lymphatic metastasis in breast cancer","volume":"17","author":"Ran","year":"2010","journal-title":"Pathophysiology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/srep05853","article-title":"Lymphatic endothelial cells support tumor growth in breast cancer","volume":"4","author":"Lee","year":"2014","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030762","article-title":"Parallels of resistance between angiogenesis and lymphangiogenesis inhibition in cancer therapy","volume":"9","author":"Jones","year":"2020","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00470","article-title":"Regulation of immune function by the lymphatic system in lymphedema","volume":"10","author":"Kataru","year":"2019","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41523-022-00486-y","article-title":"Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors","volume":"8","author":"Abdou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: Prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-019-00345-z","article-title":"Immunotherapy in triple-negative breast cancer: Present and future","volume":"11","author":"Kim","year":"2019","journal-title":"Curr Breast Cancer Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-07525-8","article-title":"Immunotherapy: an alternative promising therapeutic approach against cancers","volume":"49","author":"Gupta","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.903065","article-title":"Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities","volume":"9","author":"Ribeiro","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B30","unstructured":"Atezolizumab + Nab-paclitaxel (Tecentriq) FDA approval summary\n          \n          \n          \n          2019"},{"key":"B31","unstructured":"Pembrolizumab + chemotherapy (Keytruda) FDA Approval Summary\n          \n          \n          \n          2020"},{"key":"B32","unstructured":"Olaparib (Lynparza) FDA approval summary\n          \n          \n          \n          2018"},{"key":"B33","unstructured":"Talazoparib (Talzenna) FDA approval summary\n          \n          \n          \n          2018"},{"key":"B34","unstructured":"Sacituzumab govitecan (Trodely) FDA Approval Summary\n          \n          \n          \n          2021"},{"key":"B35","unstructured":"Pembrolizumab (Keytruda) FDA approval summary\n          \n          \n          \n          2021"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5152","article-title":"Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0862","article-title":"Clinical outcomes and immune markers by race in a phase I\/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC","volume":"28","author":"Foldi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"B39","first-page":"2121","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018"},{"key":"B40","first-page":"469","article-title":"A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer","volume":"199","author":"Yam","year":"2023"},{"key":"B41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer a phase 1 study","volume":"5","author":"Emens","year":"2019"},{"key":"B42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2767-9764.crc-22-0486","article-title":"Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma","volume":"3","author":"Shah","year":"2023"},{"key":"B43","doi-asserted-by":"publisher","first-page":"8808","DOI":"10.1002\/cam4.3487","article-title":"Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center","volume":"9","author":"Weiss","year":"2020"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-5017","article-title":"Phase I study of entinostat and nivolumab with or without ipilimumab in advanced solid tumors (ETCTN-9844)","volume":"27","author":"Torres","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s10549-023-06889-0","article-title":"A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid Malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)","volume":"198","author":"Malhotra","year":"2023"},{"key":"B46","doi-asserted-by":"publisher","first-page":"100884","DOI":"10.1016\/j.esmoop.2023.100884","article-title":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","volume":"8","author":"Hecht","year":"2023"},{"key":"B47","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837963","article-title":"Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer","volume":"12","author":"Cao","year":"2022","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6776","article-title":"A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors","volume":"13","author":"Juric","year":"2024","journal-title":"Cancer Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12916-022-02527-6","article-title":"A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer","volume":"20","author":"Zhang","year":"2022"},{"key":"B51","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41392-023-01672-5","article-title":"Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer","volume":"8","author":"Han","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","article-title":"Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence","volume":"181","author":"Brown","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e009160","DOI":"10.1136\/jitc-2024-009160","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14510","article-title":"Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer","volume":"111","author":"Toh","year":"2020","journal-title":"Cancer Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12916-024-03474-0","article-title":"Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","article-title":"Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients","volume":"22","author":"Tolaney","year":"2017","journal-title":"Oncologist"},{"key":"B58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/eo-21-0009","article-title":"SAKK 21\/12: a phase II trial of transdermal CR1447 in breast cancer patients","volume":"2","author":"Vetter","year":"2022","journal-title":"Endocr Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001011","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study","volume":"110","author":"Zheng","year":"2024","journal-title":"Int J Surg"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e000173","DOI":"10.1136\/jitc-2019-000173","article-title":"Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12967-020-02424-7","article-title":"ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer","volume":"18","author":"Kyte","year":"2020"},{"key":"B62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaoncol.2023.5424","article-title":"Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer the TBCRC 043 phase 2 randomized clinical trial","volume":"10","author":"Lehmann","year":"2024"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06128-4","article-title":"Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients","volume":"186","author":"Liu","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejca.2022.05.014","article-title":"Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: primary results and biomarker data from a phase 2 trial (WJOG9917B)","volume":"171","author":"Ozaki","year":"2022"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1158\/1078-0432.ccr-22-0622","article-title":"A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer","volume":"28","author":"Sun","year":"2022"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4726","article-title":"Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib\/II study","volume":"27","author":"Tolaney","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab plus talazoparib in patients with advanced solid tumors: the JAVELIN PARP medley nonrandomized controlled trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.011","article-title":"Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer","volume":"160","author":"Schneeweiss","year":"2022","journal-title":"Eur J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0059","article-title":"IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer","volume":"15","author":"Cort\u00e9s","year":"2019","journal-title":"Future Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.ccr-23-1349","article-title":"Phase II clinical trial of pembrolizumab and chemotherapy reveals distinct transcriptomic profiles by radiologic response in metastatic triple-negative breast cancer","volume":"30","author":"Wilkerson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1646721","article-title":"Pembrolizumab for the treatment of cervical cancer","volume":"19","author":"Marret","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J immunotherapy Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.1079","article-title":"A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP)","volume":"28","author":"Sun","year":"2021","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2019.1552255","article-title":"Atezolizumab for the treatment of triple-negative breast cancer","volume":"28","author":"Heimes","year":"2019","journal-title":"Expert Opin Invest Drugs"},{"key":"B82","article-title":"Atezolizumab is a humanized IGG1 monoclonal antibody that targets PD-L","volume":"1","author":"Saha","year":"2023","journal-title":"J Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B84","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3892\/ol.2022.13336","article-title":"Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer","volume":"24","author":"Hou","year":"2022","journal-title":"Oncol Lett"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S141491","article-title":"Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma","volume":"12","author":"Faiena","year":"2018","journal-title":"DDDT"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S141040","article-title":"Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential","volume":"12","author":"Baldini","year":"2019","journal-title":"OTT"},{"key":"B88","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/OTT.S13836","article-title":"Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval","volume":"4","author":"Yamamoto","year":"2011","journal-title":"OTT"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2217\/17435889.2.4.415","article-title":"Nanoparticle albumin-bound paclitaxel: a novel cremphor-EL\u00ae -free formulation of paclitaxel","volume":"2","author":"Stinchcombe","year":"2007","journal-title":"Nanomedicine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"Nab-paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J Controlled Release"},{"key":"B91","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12935-024-03415-0","article-title":"Key genes and molecular mechanisms related to paclitaxel resistance","volume":"24","author":"Alalawy","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecologic Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1590\/S1984-82502014000400004","article-title":"Carboplatin: molecular mechanisms of action associated with chemoresistance","volume":"50","author":"Sousa","year":"2014","journal-title":"Braz J Pharm Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00039.2021","article-title":"Lymphatic vessels in cancer","volume":"102","author":"Dieterich","year":"2022","journal-title":"Physiol Rev"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.045","article-title":"Lymphangiogenesis: molecular mechanisms and future promise","volume":"140","author":"Tammela","year":"2010","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3486","article-title":"Breast cancer metastasis and the lymphatic system","volume":"10","author":"Rahman","year":"2015","journal-title":"Oncol Lett"},{"key":"B98","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-023-01576-4","article-title":"Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions","volume":"8","author":"Ji","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.318406","article-title":"Promoting lymphangiogenesis and lymphatic growth and remodeling to treat cardiovascular and metabolic diseases","volume":"43","author":"Liu","year":"2023","journal-title":"ATVB"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133357","article-title":"Tumor microenvironment: key players in triple negative breast cancer immunomodulation","volume":"13","author":"Zheng","year":"2021","journal-title":"Cancers"},{"key":"B101","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"biomark Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e1900925","DOI":"10.1002\/adhm.201900925","article-title":"Human tumor-lymphatic microfluidic model reveals differential conditioning of lymphatic vessels by breast cancer cells","volume":"9","author":"Ayuso","year":"2020","journal-title":"Adv Healthcare Mater"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/ijc.32594","article-title":"Transcriptional profiling of breast cancer-associated lymphatic vessels reveals VCAM-1 as regulator of lymphatic invasion and permeability","volume":"145","author":"Dieterich","year":"2019"},{"key":"B104","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.3390\/cancers13236044","article-title":"Modeling tumor: lymphatic interactions in lymphatic metastasis of triple negative breast cancer","volume":"13","author":"Ji","year":"2021","journal-title":"Cancers"},{"key":"B105","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12079-017-0428-0","article-title":"A function-blocking CD47 antibody modulates extracellular vesicle-mediated intercellular signaling between breast carcinoma cells and endothelial cells","volume":"12","author":"Kaur","year":"2018"},{"key":"B106","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10585-013-9610-9","article-title":"Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model","volume":"31","author":"Lee","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1038\/ncomms5715","article-title":"Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis","volume":"5","author":"Lee","year":"2014","journal-title":"Nat Commun"},{"key":"B108","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-020-00852-y","article-title":"Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer","volume":"13","author":"Zheng","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/1535-7163.mct-18-0292","article-title":"Identification of the novel role of CD24 as an oncogenesis regulator and therapeutic target for triple-negative breast cancer","volume":"18","author":"Chan","year":"2019"},{"key":"B110","doi-asserted-by":"publisher","first-page":"R66","DOI":"10.1186\/bcr2903","article-title":"Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3","volume":"13","author":"Kodera","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00678","article-title":"Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer","volume":"64","author":"Li","year":"2021","journal-title":"J Med Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/0008-5472.can-14-2464","article-title":"Full-length semaphorin-3C is an inhibitor of tumor lymphangiogenesis and metastasis","volume":"75","author":"Mumblat","year":"2015"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14151","article-title":"Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer","volume":"23","author":"Wang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.7150\/thno.30701","article-title":"Transcriptional downregulation of miR-4306 serves as a new therapeutic target for triple negative breast cancer","volume":"9","author":"Zhao","year":"2019"},{"key":"B116","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13058-018-0981-3","article-title":"Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis","volume":"20","author":"Jin","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmy077","article-title":"CC chemokine receptor 7 promotes triple-negative breast cancer growth and metastasis","volume":"50","author":"Wu","year":"2018","journal-title":"Acta Biochim Biophys Sin"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2012.90","article-title":"Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model","volume":"92","author":"Xin","year":"2012","journal-title":"Lab Invest"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214019109","article-title":"Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells","volume":"109","author":"Schito","year":"2012","journal-title":"PNAS"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0462-2","article-title":"Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3","volume":"16","author":"Wang","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080763","article-title":"Immunotherapy treatment for triple negative breast cancer","volume":"14","author":"Berger","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B122","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102831","article-title":"The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer","volume":"130","author":"Rebaudi","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B124","doi-asserted-by":"publisher","first-page":"S266732582400133X","DOI":"10.1016\/j.fmre.2024.02.018","article-title":"Molecular biology of targeting lymphangiogenesis in cancer: Therapeutic strategies and future promise","author":"Zheng","year":"2024","journal-title":"Fundam Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.801764","article-title":"Platinum chemotherapy induces lymphangiogenesis in cancerous and healthy tissues that can be prevented with adjuvant anti-VEGFR3 therapy","volume":"12","author":"Harris","year":"2022","journal-title":"Front Oncol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"eaal4712","DOI":"10.1126\/scitranslmed.aal4712","article-title":"Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma","volume":"9","author":"Fankhauser","year":"2017","journal-title":"Sci Transl Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79434","article-title":"Lymphatic vessels regulate immune microenvironments in human and murine melanoma","volume":"126","author":"Lund","year":"2016","journal-title":"J Clin Invest"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193250","article-title":"Present and future of immunotherapy for triple-negative breast cancer","volume":"16","author":"Sriramulu","year":"2024","journal-title":"Cancers"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101893","article-title":"Small molecule agents for triple negative breast cancer: Current status and future prospects","volume":"41","author":"Ou","year":"2024","journal-title":"Transl Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201138","article-title":"Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers","volume":"34","author":"Mashayekhi","year":"2026","journal-title":"Mol Ther Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021109221","article-title":"Deciphering functional tumor states at single\u2010cell resolution","volume":"41","author":"Vegliante","year":"2022","journal-title":"EMBO J"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3390\/cells15010028","article-title":"Lymphatic endothelial cells and organ-associated lymphangiogenesis in tumor microenvironment","volume":"15","author":"Ji","year":"2025","journal-title":"Cells"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1690992","article-title":"Single-cell profiling identifies heterogeneity of the immune microenvironment in healthy, primary and lymph node metastatic BC","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1521388","article-title":"Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions","volume":"16","author":"Xin","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1641259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:34:03Z","timestamp":1776749643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1641259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":134,"alternative-id":["10.3389\/fimmu.2026.1641259"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1641259","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1641259"}}